The immunogenicity of biosimilar infliximab: Can we extrapolate the data across indications?

Expert Review of Gastroenterology and Hepatology

Volumn 9, Issue , 2015, Pages 27-34

  Ben Horin, Shomron ^a   Heap, Graham A ^b,c   Ahmad, Tariq ^b,c   Kim, HoUng ^d   Kwon, TaekSang ^d   Chowers, Yehuda ^e  

^a TEL AVIV UNIVERSITY   (Israel)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^c UNIVERSITY OF EXETER   (United Kingdom)

^d Celltrion Inc   (South Korea)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

biologics; biosimilars; CT P13; extrapolation; immunogenicity; inflammatory bowel disease, infliximab

Indexed keywords

DRUG ANTIBODY; INFLIXIMAB; ANTIINFLAMMATORY AGENT; BIOSIMILAR AGENT; CT-P13; GASTROINTESTINAL AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ANTIBODY PRODUCTION; COMPARATIVE STUDY; DRUG CONTROL; DRUG INDICATION; HUMAN; IMMUNOGENICITY; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG APPROVAL; IMMUNOLOGY; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; DRUG APPROVAL; GASTROINTESTINAL AGENTS; HUMANS; INFLAMMATORY BOWEL DISEASES; INFLIXIMAB; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84942306750     PISSN: 17474124     EISSN: 17474132     Source Type: Journal    
DOI: 10.1586/17474124.2015.1091307     Document Type: Review

References (61)

1. WHO, World Health Organization. Expert Committee on Biological Standardization. Geneva. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2009. Available from: www.who.int/biologicals/areas/biological-therapeutics/BIOTHERAPEUTICS-FOR-WEB-22APRIL2010.pdf. [Last accessed 19 February 2015]
2. European Medicines Agency. Guideline on similar biological medicinal products. 2014. www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2014/10/WC500176768.pdf. [Last accessed 16 February 2015]
3. Weise M, Kurki P, Wolff-Holz E, et al. Biosimilars: the science of extrapolation. Blood 2014; 124: 3191-6
4. Feagan BG, Choquette D, Ghosh S, et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 2014; 42: 177-83
5. Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J 2014; 16: 22-6
6. Dorner T, Strand V, Castaneda-Hernandez G, et al. The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 2013; 72: 322-8
7. Jung SK, Lee KH, Jeon JW, et al. Physicochemical characterization of Remsima. MAbs 2014; 6: 1163-77
8. European Medicines Agency. Committee for medicinal products for human use (CHMP). Assessment report: Remsima (infliximab). 2013. Available from: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002576/WC500151486.pdf. [Last accessed 20 August 2015]
9. Yoo DH, Hrycaj P, Miranda P, et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann Rheum Dis 2013; 72: 1613-20
10. Park W, Hrycaj P, Jeka S, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis 2013; 72: 1605-12
11. De Groot AS, Scott DW. Immunogenicity of protein therapeutics. Trends Immunol 2007; 28: 482-90
12. Allez M, Karmiris K, Louis E, et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355-66
13. Sauerborn M, Brinks V, Jiskoot W, et al. Immunological mechanism underlying the immune response to recombinant human protein therapeutics. Trends Pharmacol Sci 2010; 31: 53-9
14. Lichtenstein GR. Comprehensive review: antitumor necrosis factor agents in inflammatory bowel disease and factors implicated in treatment response. Therap Adv Gastroenterol 2013; 6: 269-93
15. Ben-Horin S, Chowers Y. Tailoring anti-TNF therapy in IBD: drug levels and disease activity. Nat Rev Gastroenterol Hepatol 2014; 11: 243-55
16. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-8
17. Chirmule N, Jawa V, Meibohm B. Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy. AAPS J 2012; 14: 296-302
18. Cohen BA, Oger J, Gagnon A, et al. The implications of immunogenicity for protein-based multiple sclerosis therapies. J Neurol Sci 2008; 275: 7-17
19. Ragnhammar P, Friesen HJ, Frodin JE, et al. Induction of anti-recombinant human granulocyte-macrophage colony-stimulating factor (Escherichia coli-derived) antibodies and clinical effects in nonimmunocompromised patients. Blood 1994; 84: 4078-87
20. Van Haeften TW. Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care 1989; 12: 641-8
21. Walford S, Allison SP, Reeves WG. The effect of insulin antibodies on insulin dose and diabetic control. Diabetologia 1982; 22: 106-10
22. Tovey MG, Lallemand C. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Saf 2011; 2: 113-28
23. Tamilvanan S, Raja NL, Sa B, et al. Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body. J Drug Target 2010; 18: 489-98
24. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013; 9: 164-72
25. Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-Alpha-1,3-galactose. N Engl J Med 2008; 358: 1109-17
26. Harding FA, Stickler MM, Razo J, et al. The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs 2010; 2: 256-65
27. Rosenberg AS. Effects of protein aggregates: an immunologic perspective. AAPS J 2006; 8: E501-7
28. Locatelli F, Del Vecchio L, Pozzoni P. Pure red-cell aplasia "epidemic"-mystery completely revealed? Perit Dial Int 2007; 27 (Suppl 2): S303-7
29. Billiet T, Vande Casteele N, Van Stappen T, et al. Immunogenicity to infliximab is associated with HLA-DRB1. Gut 2015; 63: 1344-5
30. Ben-Horin S, Yavzori M, Katz L, et al. The immunogenic part of infliximab is the F(ab)2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-8
31. Pascual-Salcedo D, Plasencia C, Ramiro S, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011; 50: 1445-52
32. Garces S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-Analysis. Ann Rheum Dis 2013; 72: 1947-55
33. Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated Inflammatory conditions: systematic review and meta-Analysis. JAMA Intern Med 2013; 173: 1416-28
34. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohns disease. Clin Gastroenterol Hepatol 2004; 2: 542-53
35. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohns disease. N Engl J Med 2003; 348: 601-8
36. Vermeire S, Noman M, Van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohns disease. Gut 2007; 56: 1226-31
37. Jung SM, Kim HS, Kim HR, et al. Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis. Int Immunopharmacol 2014; 21: 20-5
38. Plasencia C, Pascual-Salcedo D, Nuno L, et al. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012; 71: 1955-60
39. Steenholdt C, Svenson M, Bendtzen K, et al. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34: 51-8
40. Ben-Horin S, Yavzori M, Benhar I, et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut 2015. [Epub ahead of print]
41. Brinks V. Immunogenicity of biosimilar monoclonal antibodies. Generics Biosimilars Initiat J 2013; 2: 188-93
42. Yoo DH, Racewicz A, Brzezicki J, et al. A phase 3 randomised controlled trial to compare CT-P13 with infliximab in patients with active rheumatoid arthritis: 54 week results from the PLANETRA study. Ann Rheum Dis 2013; 72 (Suppl 3): 73. [OP0068]
43. Park W, Jaworski J, Brzezicki J, et al. A randomised, double-blind, parallel-group, phase 1 study comparing the pharmacokinetics, safety and efficacy of CT-P13 and infliximab in patients with active ankylosing spondylitis: 54 week results from the PLANETAS study. Ann Rheum Dis 2013; 72 (Suppl 3): 516. [FRI0421]
44. Park W, Miranda P, Brzosko M, et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13. Arthritis Rheum 2013; 65: 3326. (L15)
45. Yoo D, Prodanovic N, Jaworski J, et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P13 and switching from infliximab to CT-P13. Arthritis Rheum 2013; 65: 3319. (L1)
46. Fiorino G, Danese S. The biosimilar road in inflammatory bowel disease: the right way? Best Pract Res Clin Gastroenterol 2014; 28: 465-71
47. Cassinotti A, Travis S. Incidence and clinical significance of immunogenicity to infliximab in Crohns disease: a critical systematic review. Inflamm Bowel Dis 2009; 15: 1264-75
48. Jani M, Barton A, Warren RB, et al. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014; 53: 213-22
49. European Medicines Agency. Remicade (infliximab). Summary of Product Characteristics. 2014. Available from: www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000240/WC500050888.pdf. [Last accessed 19 July 2015]
50. Steenholdt C, Bendtzen K, Brynskov J, et al. Clinical implications of measuring drug and anti-drug antibodies by different assays when optimizing infliximab treatment failure in Crohns disease: post hoc analysis of a randomized controlled trial. Am J Gastroenterol 2014; 109: 1055-64
51. Vande Casteele N, Khanna R, Levesque BG, et al. The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohns disease. Gut 2014. [Epub ahead of print]
52. Ungar B, Anafy A, Yanai H, et al. Significance of low level infliximab in the absence of anti-infliximab antibodies. World J Gastroenterol 2015; 21: 1907-14
53. Ungar B, Chowers Y, Yavzori M, et al. The temporal evolution of antidrug antibodies in patients with inflammatory bowel disease treated with infliximab. Gut 2014; 63: 1258-64
54. Steenholdt C, Al-khalaf M, Brynskov J, et al. Clinical implications of variations in anti-infliximab antibody levels in patients with inflammatory bowel disease. Inflamm Bowel Dis 2012; 18: 2209-17
55. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol 2013; 108: 962-71
56. Feagan BG, McDonald JW, Panaccione R, et al. Methotrexate in combination with infliximab is no more effective than infliximab alone in patients with Crohns disease. Gastroenterology 2014; 146: 681-8 e1
57. St Clair EW, Wagner CL, Fasanmade AA, et al. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-9
58. Demonstrate Noninferiority in Efficacy and to Assess Safety of CT-P13 in Patients With Active Crohns Disease. Available from: https://clinicaltrials.gov/ct2/show/NCT02096861
59. The NOR-SWITCH Study. Available from: https://clinicaltrials.gov/ct2/show/NCT02148640
60. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 2010; 1: 314-22
61. Wirth M, Heidenreich A, Gschwend JE, et al. A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy. Eur Urol 2014; 65: 897-904